{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:23:10Z","timestamp":1787768590072,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate the incidence and risk factors for steroid-induced ocular hypertension (SI-OHT) in patients receiving intravitreal steroids for retinal inflammatory diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective observational study included patients who received either intravitreal triamcinolone acetonide (IVTA\/TA group) or dexamethasone intravitreal implant (DEX group) for the management of retinal vascular diseases in the period of 2018\u201323. SI-OHT in those patients were followed up for 2 years. Steroid responders and nonresponders were characterized based on intraocular pressure (IOP) change from the baseline. The incidence, risk factors, and magnitude of IOP rise and its association with ocular and systemic illness were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Out of 1178 reviewed, 761 patients were excluded due to irregular follow-up. A total of 382 patients (382 eyes) who received either IVTA\/DEX intravitreal implant during the study period were reviewed. The incidence of SI-OHT was found to be 46.3% (IVTA group) and 20.8% (DEX group) at 6 months, respectively. Among patients who received 2 mg IVTA dosage, 16.9% were steroid responders and 11.9% for the 4 mg group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We found that the incidence of SI-OHT was higher in IVTA group as compared to DEX group. No dose-dependent incidence was observed in the case of IVTA group. Age, gender, number of injections, and myopia were not associated with the risk of SI-OHT. Renal disease showed a significant association with the risk of SI-OHT in the DEX group, and patients with TB, stroke, and other drug allergies experienced a fivefold greater increase in IOP values in those groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1481_25","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:00:40Z","timestamp":1767787240000},"page":"362-367","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective study reporting the incidence, risk factors, and intraocular pressure rise in patients receiving intravitreal steroids for retinal inflammatory diseases in a tertiary eye care hospital of South India"],"prefix":"10.4103","volume":"74","author":[{"given":"Srinivasan","family":"Senthilkumari","sequence":"first","affiliation":[{"name":"Department of Ocular Pharmacology, Aravind Medical Research Foundation, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendrababu","family":"Sharmila","sequence":"additional","affiliation":[{"name":"Glaucoma Clinic, Aravind Eye Hospital, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mani","family":"Ishwarya","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Aravind Eye Hospital, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan B","family":"Naresh","sequence":"additional","affiliation":[{"name":"Vitreo-Retinal Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"R1-20260417","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.preteyeres.2016.09.003","article-title":"Steroid-induced ocular hypertension\/glaucoma: Focus on pharmacogenomics and implications for precision medicine","volume":"56","author":"Fini","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"R2-20260417","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3928\/15428877-20100215-95","article-title":"Intravitreal triamcinolone acetonide use in diabetic macular edema: Illustrative cases","volume":"41","author":"Schwartz","year":"2010","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R3-20260417","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bjo.2004.046391","article-title":"Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: A comparative, non-randomised study","volume":"89","author":"Jonas","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R4-20260417","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/01.iae.0000237111.82357.30","article-title":"One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion","volume":"26","author":"Gregori","year":"2006","journal-title":"Retina"},{"key":"R5-20260417","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"R6-20260417","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R7-20260417","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"R8-20260417","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: Thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"R9-20260417","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.survophthal.2012.08.003","article-title":"Intraocular pressure monitoring post intravitreal steroids: A systematic review","volume":"58","author":"Kiddee","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"R10-20260417","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.18240\/ijo.2020.08.17","article-title":"Assessment of single nucleotide polymorphisms associated with steroid-induced ocular hypertension","volume":"13","author":"Badrinarayanan","year":"2020","journal-title":"Int J Ophthalmol"},{"key":"R11-20260417","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000522504","article-title":"Incidence, risk factors, treatment, and outcome of ocular hypertension following intravitreal steroid injections: A comparative study","volume":"245","author":"Badrinarayanan","year":"2022","journal-title":"Ophthalmologica"},{"key":"R12-20260417","first-page":"187","article-title":"Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response","volume":"4","author":"Armaly","year":"1965","journal-title":"Invest Ophthalmol"},{"key":"R13-20260417","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ajo.2007.04.021","article-title":"Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone","volume":"144","author":"Shukla","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R14-20260417","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bjo.2006.090340","article-title":"Intraocular pressure alterations following intravitreal triamcinolone acetonide","volume":"90","author":"Rhee","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R15-20260417","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1111\/j.1755-3768.2011.02247.x","article-title":"Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema","volume":"90","author":"Sallam","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"R16-20260417","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archopht.121.1.57","article-title":"Intravitreal injection of triamcinolone for diffuse diabetic macular edema","volume":"121","author":"Jonas","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R17-20260417","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ajo.2004.06.067","article-title":"Intravitreal triamcinolone acetonide and intraocular pressure","volume":"138","author":"Smithen","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R18-20260417","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jamaophthalmol.2015.1823","article-title":"Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE study report 15","volume":"133","author":"Aref","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R19-20260417","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/IAE.0000000000001004","article-title":"Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study","volume":"36","author":"Maturi","year":"2016","journal-title":"Retina"},{"key":"R20-20260417","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1097\/IAE.0000000000000726","article-title":"Intravitreal corticosteroids in diabetic macular edema: Pharmacokinetic considerations","volume":"35","author":"Yang","year":"2015","journal-title":"Retina"},{"key":"R21-20260417","first-page":"139","article-title":"Changes of intraocular pressure after intravitreal injection of 4 mg triamcinolone acetonide in treatment of macular edema","volume":"1","author":"Wang","year":"2008","journal-title":"Int J Ophthalmol"},{"key":"R22-20260417","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/IAE.0000000000001364","article-title":"Ocular hypertension after intravitreal dexamethasone (ozurdex) sustained-release implant","volume":"37","author":"Chin","year":"2017","journal-title":"Retina"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1481_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:15:59Z","timestamp":1787768159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1481_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1481_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2025-06-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}